STOCK TITAN

Cencora Inc. - COR STOCK NEWS

Welcome to our dedicated page for Cencora news (Ticker: COR), a resource for investors and traders seeking the latest updates and insights on Cencora stock.

About Cencora Inc. (Symbol: COR)

Cencora Inc., formerly known as AmerisourceBergen, stands as a pivotal player in the global healthcare supply chain, specializing in pharmaceutical distribution and related services. Operating at the intersection of healthcare delivery and supply chain logistics, Cencora ensures the efficient and secure distribution of branded, generic, and specialty pharmaceuticals, as well as over-the-counter (OTC) healthcare products. Its services are integral to pharmacies, hospital networks, healthcare providers, and pharmaceutical manufacturers, making it a cornerstone of the healthcare ecosystem.

Core Business Operations

Cencora’s business model is built around three primary pillars:

  • Pharmaceutical Distribution: Cencora sources and distributes a wide range of pharmaceutical products to retail pharmacies (chains and independents), mail-order pharmacies, and healthcare providers. Its streamlined operations enhance product accessibility, cost-efficiency, and supply chain reliability.
  • Commercialization and Manufacturer Services: The company offers end-to-end solutions for pharmaceutical and medical device manufacturers, maximizing product success throughout the lifecycle. These services include market access strategies, regulatory support, and commercialization solutions.
  • Specialty Logistics and Animal Health: Through its World Courier division, Cencora provides global specialty drug logistics, ensuring the secure and timely delivery of high-value, temperature-sensitive pharmaceuticals. Additionally, its MWI Animal Health segment focuses on the distribution of animal health products, catering to veterinary practices and agricultural businesses.

Global Reach and Strategic Expansion

While Cencora is a dominant player in the U.S. pharmaceutical wholesale market, alongside competitors McKesson and Cardinal Health, it has significantly expanded its international footprint. In 2021, the acquisition of Alliance Healthcare, a leading drug wholesaler in Europe, marked a strategic move to strengthen its global presence. This expansion positions Cencora as a key player in both domestic and international markets, enabling it to leverage economies of scale and enhance its service offerings.

Value Proposition

Cencora’s value proposition lies in its ability to streamline the healthcare supply chain, ensuring that medications and healthcare products are delivered securely, consistently, and cost-effectively. By improving product access for pharmacies, providers, and patients, the company plays a critical role in enhancing healthcare delivery. Additionally, its tailored solutions for manufacturers and providers drive operational efficiency, cost control, and patient safety, further solidifying its importance in the industry.

Competitive Positioning

As one of the “Big Three” pharmaceutical wholesalers in the U.S., Cencora holds a significant market share, alongside McKesson and Cardinal Health. Together, these three companies account for over 90% of the U.S. pharmaceutical wholesale market. Cencora differentiates itself through its specialized services, such as global logistics via World Courier and its focus on animal health through MWI Animal Health. Its strategic acquisitions and commitment to innovation further bolster its competitive edge.

Industry Significance

The pharmaceutical wholesale industry is a critical component of the healthcare system, ensuring the timely and efficient distribution of life-saving medications. Cencora’s role in this ecosystem extends beyond distribution; its comprehensive service offerings address the complexities of pharmaceutical commercialization, logistics, and supply chain management. By bridging the gap between manufacturers and end-users, Cencora contributes to improved healthcare outcomes worldwide.

Conclusion

Cencora Inc. exemplifies the integration of expertise, innovation, and operational excellence in the healthcare supply chain. Its diverse business segments, strategic global expansion, and focus on enhancing healthcare delivery position it as a trusted partner for stakeholders across the healthcare spectrum. As the healthcare landscape continues to evolve, Cencora’s role in shaping efficient and effective delivery systems remains indispensable.

Rhea-AI Summary
Cencora, Inc. (NYSE: COR) plans to release its First Quarter Fiscal 2024 results on January 31, 2024, followed by a conference call with Chairman, President & CEO Steven H. Collis and CFO James F. Cleary. The live call will be webcast on investor.cencora.com, with replays available via telephone and webcast. Access codes provided for both live and replay calls.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
-
Rhea-AI Summary
Sapphiros (COR) partners with Cencora, Inc. to distribute COVID-19 Antigen Rapid Tests and future diagnostic technologies, aiming to enhance accessibility and convenience for consumers nationwide. The agreement also includes access to upcoming Sapphiros technologies, such as multiplexed molecular diagnostics platform, rapid lateral flow tests for diseases beyond COVID-19, and the Satio™ blood collection patch in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
none
-
Rhea-AI Summary
Cencora, Inc. (NYSE: COR) announces agreement to repurchase $250 million worth of common stock from Walgreens Boots Alliance Holdings LLC in concurrence with Rule 144 transactions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
buyback
Rhea-AI Summary
Walgreens Boots Alliance (WBA) announced the sale of shares of Cencora, Inc. (COR) through variable prepaid forward transactions, generating $424 million in current proceeds and potentially more at maturity. The company also conducted a concurrent share repurchase by Cencora for $250 million. The proceeds will be used for debt paydown and general corporate purposes, with no dilutive impact on adjusted EPS until the contracts mature in Q4 of fiscal year 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
-
Rhea-AI Summary
Cencora, Inc. (NYSE: COR) reported a 12.7% YoY increase in revenue to $68.9 billion for Q4 2023. For the fiscal year 2023, revenue increased 9.9% to $262.2 billion. GAAP diluted EPS for Q4 was $1.72, while adjusted diluted EPS was $2.86. For the fiscal year, GAAP diluted EPS was $8.53 and adjusted diluted EPS was $11.99.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.64%
Tags
-
Rhea-AI Summary
Cencora, Inc. (NYSE: COR) plans to release Q4 2023 results on November 2, 2023, before the opening of trading on NYSE. Conference call to discuss results at 8:30 a.m. ET. Webcast available on investor.cencora.com. Replays available via telephone and webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
Rhea-AI Summary
Cencora, Inc. completes name and stock ticker change, announces $5 million commitment to philanthropy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
none
-
Rhea-AI Summary

CoreSite Realty Corporation, a subsidiary of American Tower, announced tax reporting information for its 2021 distributions. Following the acquisition by American Tower on December 28, 2021, CoreSite's shares ceased trading on the NYSE. Stockholders are advised to consult tax advisors regarding their specific tax treatment. For the year, CoreSite reported cash distributions per share, including ordinary taxable dividends and capital gain distributions, emphasizing that there were no non-dividend distributions for the tax year ending December 28, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
none
-
Rhea-AI Summary

American Tower Corporation (NYSE: AMT) has successfully completed its acquisition of CoreSite Realty Corporation (NYSE: COR) following a tender offer for CoreSite's outstanding shares. The acquisition was financed through borrowings under American Tower’s credit facilities and term loans. CEO Tom Bartlett expressed optimism about leveraging CoreSite's data centers to enhance growth opportunities amidst the rise of 5G and cloud services. The acquisition is expected to be modestly accretive to American Tower’s AFFO per Share initially, with potential for increased accretion over time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
Rhea-AI Summary

American Tower Corporation (NYSE: AMT) announced the expiration of its tender offer for CoreSite Realty Corporation (NYSE: COR) shares, completing the acquisition via a merger with its subsidiary, Appleseed Merger Sub LLC. The tender offer, which ended on December 27, 2021, resulted in 31,443,126 shares tendered, accounting for approximately 71.15% of CoreSite's outstanding shares. CoreSite will merge into American Tower on December 28, 2021, with its shares ceasing to trade on the NYSE. Each CoreSite share will convert to $170.00 in cash, matching the tender offer price.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
none

FAQ

What is the current stock price of Cencora (COR)?

The current stock price of Cencora (COR) is $279.15 as of April 10, 2025.

What is the market cap of Cencora (COR)?

The market cap of Cencora (COR) is approximately 54.1B.

What does Cencora Inc. do?

Cencora Inc. specializes in pharmaceutical distribution, supply chain solutions, and related services, supporting pharmacies, healthcare providers, and manufacturers.

How does Cencora generate revenue?

Cencora generates revenue through pharmaceutical distribution, commercialization services for manufacturers, global logistics, and animal health product distribution.

What is Cencora's competitive position in the industry?

Cencora is one of the top three pharmaceutical wholesalers in the U.S., alongside McKesson and Cardinal Health, collectively dominating over 90% of the market.

What industries does Cencora serve?

Cencora serves the pharmaceutical, healthcare, and animal health industries, providing distribution, logistics, and commercialization solutions.

What are Cencora's key business segments?

Cencora's key business segments include pharmaceutical distribution, manufacturer services, specialty logistics (World Courier), and animal health (MWI Animal Health).

How has Cencora expanded internationally?

Cencora expanded its global presence by acquiring Alliance Healthcare in 2021, a leading European drug wholesaler, to strengthen its international operations.

What is Cencora's role in the healthcare supply chain?

Cencora ensures the efficient, secure, and cost-effective distribution of pharmaceuticals, enhancing product access for pharmacies, providers, and patients.

What is World Courier, and how is it related to Cencora?

World Courier is a division of Cencora specializing in global specialty drug logistics, ensuring the secure delivery of high-value, temperature-sensitive pharmaceuticals.

What is MWI Animal Health, and what does it do?

MWI Animal Health, a division of Cencora, focuses on the distribution of animal health products, serving veterinary practices and agricultural businesses.

How does Cencora support pharmaceutical manufacturers?

Cencora provides end-to-end commercialization solutions for manufacturers, including market access strategies, regulatory support, and product lifecycle management.
Cencora Inc.

NYSE:COR

COR Rankings

COR Stock Data

54.08B
182.61M
6.85%
92.69%
3.58%
Medical Distribution
Wholesale-drugs, Proprietaries & Druggists' Sundries
Link
United States
CONSHOHOCKEN